FOR HEALTHCARE PROFESSIONALS ONLY

This website is a global information resource. It is intended for healthcare professionals only outside of the United States of America (US) who are interested in information on Foundation Medicine®. This site is not intended to provide medical advice and/or treatment guidance. If you are a US healthcare professional click here.

This site is produced by Roche as a partner of Roche Foundation Medicine.

Naš portfolio
 

Visoko kvalitetni portfolio

Izbor Foundation Medicine vrhunskih genskih testova za precizno dijagnosticiranje raka

Visokokvalitetne Foundation Medicine usluge za sveobuhvatno gensko testiranje pomažu ljekarima  personalizirati liječenje za pacijente u različitim kliničkim situacijama:1–4
All our services use our leading comprehensive genomic profiling approach to identify clinically relevant alterations and potentially expand treatment options

Sve Foundation Medicine usluge koriste naš vodeći sveobuhvatni pristup genskom profiliranju, koji  temeljno analizira tumorski genom kako bi utvrdio klinički značajne promjene i potencijalno proširio mogućnosti liječenja pacijenata.5-10
Genska baza podataka

 

Kako se povećava naše znanje o raku, tako se razvijaju i naši testovi

Naša genska baza podataka trenutno uključuje preko 200.000 genskih profila u preko 150 čestih i rijetkih podtipova malignih tumora. Napredna bioinformatika interpretira podatke, uključujući rijetke i složene promjene, kako bi stekli kompletan uvid. 1,6 Naši testovi se neprestano razvijaju kako bi obuhvatili klinički najznačajnije genske promjene zajedno s mogućim ciljanim terapijama  i dostupnim kliničkim ispitivanjima.1,6

Our growing database includes 200,000+ genomic profiles, allowing our tests to constantly evolve so we can provide the most clinically relevant insights
References
  1. FoundationOne®CDx Technical Specifications, 2018. Available at: www.rochefoundationmedicine.com/f1cdxtech (Accessed March 2019).
  2. FoundationOne®CDx FDA Approval, 2017. Available at: https://www.accessdata.fda.gov/cdrh_docs/pdf17/P170019a.pdf (Accessed March 2019).
  3. FoundationOne®Liquid Technical Specifications, 2018. Available at: https://www.foundationmedicine.com/genomic-testing/foundation-one-liquid (Accessed March 2019).
  4. FoundationOne®Heme Technical Specifications, 2017. Available at: www.foundationmedicine.com/genomic-testing/foundation-one-heme (Accessed March 2019).
  5. Drilon A et al. Clin Cancer Res 2015; 21: 3631–3639.
  6. Frampton GM et al. Nat Biotechnol 2013; 31: 1023–1031.
  7. Rankin A et al. Oncologist 2016; 21: 1306–1314.
  8. Ross JS et al. Cancer 2016; 122: 2654–2662.
  9. Suh JH et al. Oncologist 2016; 21: 684–691.
  10. Hirshfield KM et al. Oncologist 2016; 21: 1315–1325.
  11. Foundation Insights. Available at: https://www.foundationmedicine.com/insights-and-trials/foundation-insights (Accessed March 2019).